DOCSLIB.ORG

Oral History Interview with Lawrence Bachorik Director Office of Communications 1978-2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Oral History Interview with Lawrence Bachorik Director Office of Communications 1978-2015 FDA Oral History Program Final Edited Transcript July 18, 2016 Table of Contents Table of Contents ............................................................................................................................ 2 Oral History Abstract ...................................................................................................................... 3 Keywords ........................................................................................................................................ 3 Citation Instructions ........................................................................................................................ 3 Interviewer Biography .................................................................................................................... 4 FDA Oral History Program Mission Statement .............................................................................. 4 Statement on Editing Practices ....................................................................................................... 4 Index ............................................................................................................................................... 5 Interview Transcript ........................................................................................................................ 9 Curriculum Vitae ........................................................................................................................ 247 Deed of Gift ................................................................................................................................ 249 Lawrence Bachorik Oral History 2 Lawrence Bachorik, c. 2013 Oral History Abstract Lawrence Bachorik came to FDA in the fall of 1978, as a speechwriter in the Office of the Commissioner. Over the next three and half decades he played an instrumental role in developing and administering FDA communications and media relations, writing speeches for Commissioners Donald Kennedy, David Kessler, and Jane Henney, and starting FDA’s Office of Public Affairs (now the Office of External Affairs). Keywords public affairs; media; public information; speechwriting; communications; stakeholders Citation Instructions This interview should be cited as follows: “Lawrence Bachorik Oral History Interview,” History Office, U.S. Food and Drug Administration, Department of Health and Human Services, July 18, 2016. Lawrence Bachorik Oral History 3 Interviewer Biography Catherine Copp, J.D. is former Associate Counsel for Foods and Policy Advisor in FDA’s Center for Food Safety and Applied Nutrition. Prior to her work in CFSAN, Catherine served in FDA’s Office of General Counsel for over fifteen years. She retired after thirty years at FDA, and joined the FDA History Office as an oral historian. She earned her law degree from the University of Michigan. Suzanne Junod, Ph.D. is an historian in the FDA History Office at the U.S. Food and Drug Administration. Soon after beginning her career at FDA in 1984, Suzanne helped to organize the FDA History Office. She is a subject matter expert in FDA history and her scholarly writings have been published in the Food, Drug, and Cosmetic Law Journal, the Journal of Federal History, and the Journal of the History of Medicine and Allied Sciences, as well as edited compilations. She earned her Ph.D. at Emory University in Atlanta, where she studied under James Harvey Young. FDA Oral History Program Mission Statement The principal goal of FDA’s OHP is to supplement the textual record of the Agency’s history to create a multi-dimensional record of the Agency’s actions, policies, challenges, successes, and workplace culture. The OHP exists to preserve institutional memory, to facilitate scholarly and journalistic research, and to promote public awareness of the history of the FDA. Interview transcripts are made available for public research via the FDA website, and transcripts as well as audio recordings of the interviews are deposited in the archives of the National Library of Medicine. The collection includes interviews with former FDA employees, as well as members of industry, the academy and the legal and health professions with expertise in the history of food, drug and cosmetic law, policy, commerce and culture. These oral histories offer valuable first-person perspectives on the Agency’s work and culture, and contribute otherwise undocumented information to the historical record. Statement on Editing Practices It is the policy of the FDA Oral History Program to edit transcripts as little as possible, to ensure that they reflect the interviewee’s comments as accurately as possible. Minimal editing is employed to clarify mis-starts, mistakenly conveyed inaccurate information, archaic language, and insufficiently explained subject matter. FDA historians edit interview transcripts for copy and content errors. The interviewee is given the opportunity to review the transcript and suggest revisions to clarify or expand on interview comment, as well as to protect their privacy, sensitive investigative techniques, confidential agency information, or trade secrets. Lawrence Bachorik Oral History 4 Index abortifascients Codex Alimentarius, 217 mifepristone (RU-486), 170 congressional affairs abortifscients Barton, Joseph, 133 mifepristone (RU-486), 177 leadership, 182 aspirin, 50, 52, 53 testimony, 103, 106, 133 Benson, James (Jim), 33, 62, 63, 71 Corey, Beverly. See Blackwell, Michael, 129 Cox, Virginia, 226 bovine spongiform encephalopathy (BSE), Crawford, Lester, 181, 209, 211 124, 125, 127 Crout, Richard (Dick), 28 Brand, Daniel, 40 Deighton, Gerry, 102 buildings Department of Health and Human Services Parklawn Building, 21, 26, 28, 56, 72, 79, relationship with FDA, 229 142, 143, 145, 151, 165, 228 deregulation, 29, 45 cancer fraud impact on FDA work culture, 56 Burzynski, Stanislov, 139 President's Council on Regulatory Relief, Cannon, Hugh, 68 46 career dietary supplements, 112, 115 Assistant Commissioner for External Dietary Supplement Health and Education Relations, 220 Act (DSHEA), 113 Associate Commissioner for Public Dingell, John, 120 Affairs, 98, 168 District Directors Commissioner’s speechwriter, 54, 55, public affairs, 235 210, 219 editing congressional testimony, 49 food labeling regulations, 29, 31 director of public relations at Fairfax medical device regulations, 31 Hospital Association (Inova Health education, 9 System), 57, 243 Ph.D. in 18th Century British literature, director of speechwriters, Office of Public 10 Affairs, 61 Edwards Committee, 69 George Mason University, 14 Edwards, Charles (Charlie), 69 George Washington University, 13 European Medicines Evaluation Agency Georgetown University, 12 (EMEA), 212 Office of Public Affairs, 54 external communications policy analyst, 47 digital communications, 98 recruitment to FDA, 15 FDA Consumer Updates, 222 return to FDA, 60 FDA Voice blog, 226 speechwriter, 39 external communications (media affairs), 90, training specialist, 38 92, 94, 95, 100, 123, 132, 141, 142, 162 writer/editor, Office of Policy interview clearance process, 215, 216 Coordination, 16, 20, 24 external communications (public affairs) centralization press releases, 194 human resources, 190 rollouts, 210 Chesemore, Ronald, 80 Talk Papers, 194 Chief Counsel, 203 Fairfax Hospital Association/INOVA Lawrence Bachorik Oral History 5 communications, 58 newsletter, 224, 225, 226 Feigal, David, 136 internal/external communications Flieger, Ken, 45 Commissioner's correspondence, 19, 23, Food and Drug Administration 27, 35 Modernization Act (FDAMA), 145 complex subject matter, 34 Food and Drug Law Institute (FDLI) annual Operation SHAKESPEARE, 24, 25, 26, meeting 27, 28, 29, 31 FDA Commissioner speeches, 70, 73, 74, plain language, 21, 22, 29 106, 107, 110 style guide, 25 food contamination training, 27, 28 Odwalla juice, 130, 148, 150, 151 international affairs, 213 food labeling, 66, 116, 117 imports, 174 fresh, 85, 88 investigational new drug (IND), 50 Freedom of Information (FOI) requests, 101, Kennedy, Donald, 14, 18, 19, 21, 22, 23, 24, 102 25, 26, 27, 29, 32, 35, 36, 43, 48, 49, 51, Friedman, Michael, 144, 145, 146, 161, 162, 78, 185 164, 165 notoriety, 78 generic drug scandal, 64, 65 Kessler, David, 47, 49, 63, 67, 68, 69, 70, Gladwell, Malcolm, 64 72, 73, 74, 76, 77, 80, 82, 84, 85, 86, 87, Gottlieb, Scott, 218 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, Goyan, Jere, 27, 35, 36, 37, 179 100, 103, 104, 106, 108, 109, 110, 111, Grumbly, Thomas, 14 112, 113, 114, 115, 116, 117, 118, 120, Halperin, Jerry, 28 126, 130, 131, 132, 133, 134, 139, 140, Hamburg, Margaret (Peggy), 222 141, 144, 145, 146, 148, 149, 150, 151, Hayes, Arthur, 37, 39, 44, 46, 54, 107 152, 153, 158, 159, 160, 161, 162, 164, headquarters-field relations, 82, 228, 229, 167, 172, 173, 175, 199, 245 234, 235 leadership, 154, 157, 158 Henney, Jane, 102, 109, 112, 144, 160, 161, notoriety, 78, 79 163, 164, 165, 166, 167, 168, 169, 170, scholarly publications, 159 171, 172, 176, 177, 178, 179, 180, 181, work ethic, 154 182, 183, 185, 186 Kubic, Milan (Mike), 62 hiring, 199 Larkin, Timothy, 36, 37 HIV/AIDS, 80, 108, 110 Levitt, Joseph (Joe), 60, 62 ACTUP protest, 79 L-tryptophan, 112 blood supply safety, 119, 120, 121 Lumpkin, Mac, 218 Hubbard, William (Bill), 59, 60 Martin, Jack, 68 human tissue safety, 207 Martino, Elizabeth (Beth), 224 information technology McClellan, Mark, 109, 182, 192, 193, 194, Wang word
Recommended publications
  • Janet Woodcock, MD Director of the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA)

    Janet Woodcock, MD Director of the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA)

    Janet Woodcock, MD Director of the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) Janet Woodcock is the director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). The center makes sure that safe and effective drugs are available to improve the health of people in the United States. Dr. Woodcock and her center: • evaluate prescription and over the counter drugs before they can be sold and oversee their testing in clinical trials • provide health care professionals and patients the information they need to use medicines wisely • ensure that drugs, both brand-name and generic, work correctly and that their health benefits outweigh their known risks • take action against unapproved, contaminated, or fraudulent drugs that are marketed illegally "New drugs—and new uses for older drugs—save lives, reduce suffering, and improve the quality of life for millions of Americans," says Dr. Woodcock. "I am continually challenged to make sure that FDA’s regulatory process remains the world's gold standard for drug approval and safety." Dr. Woodcock has led many of FDA's drug initiatives. She introduced the concept of risk management in 2000 as a new approach to drug safety. Since 2002, she has led the "Pharmaceutical Quality for the 21st Century Initiative," FDA's highly successful effort to modernize drug manufacturing and its regulation. In 2004, she introduced FDA's "Critical Path" Initiative, which is designed to move medical discoveries from the laboratory to consumers more efficiently. Most recently, Dr. Woodcock launched the "Safety First" and "Safe Use" initiatives designed to improve drug safety management within and outside FDA, respectively.
  • Overruling the Food and Drug Administration

    Overruling the Food and Drug Administration

    Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Alisha Crovetto, Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action (May 2012). Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10985168 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action Alisha Crovetto Harvard Law School J.D. Candidate, 2013 May 2012 Food & Drug Law Course Paper Abstract On December 7, 2011, newspaper headlines from coast to coast announced that Plan B One-Step, a form of emergency contraception, would not be made available to females under seventeen without a prescription. The denial of over-the-counter (“OTC”) status, though newsworthy itself, drew particular attention because of the unusual nature of the decision. As the New York Times announced, “[f]or the first time ever, the Health and Human Services secretary publicly overruled the Food and Drug Administration .
  • Masakazu Konishi

    Masakazu Konishi

    Masakazu Konishi BORN: Kyoto, Japan February 17, 1933 EDUCATION: Hokkaido University, Sapporo, Japan, B.S. (1956) Hokkaido University, Sapporo, Japan, M.S. (1958) University of California, Berkeley, Ph.D. (1963) APPOINTMENTS: Postdoctoral Fellow, University of Tübingen, Germany (1963–1964) Postdoctoral Fellow, Division of Experimental Neurophysiology, Max-Planck Institut, Munich, Germany (1964–1965) Assistant Professor of Biology, University of Wisconsin, Madison (1965–1966) Assistant Professor of Biology, Princeton University (1966–1970) Associate Professor of Biology, Princeton University (1970–1975) Professor of Biology, California Institute of Technology (1975– 1980) Bing Professor of Behavioral Biology, California Institute of Technology (1980– ) HONORS AND AWARDS (SELECTED): Member, American Academy of Arts and Sciences (1979) Member, National Academy of Sciences (1985) President, International Society for Neuroethology (1986—1989) F. O. Schmitt Prize (1987) International Prize for Biology (1990) The Lewis S. Rosenstiel Award, Brandeis University (2004) Edward M. Scolnick Prize in Neuroscience, MIT (2004) Gerard Prize, the Society for Neuroscience (2004) Karl Spencer Lashley Award, The American Philosophical Society (2004) The Peter and Patricia Gruber Prize in Neuroscience, The Society for Neuroscience (2005) Masakazu (Mark) Konishi has been one of the leaders in avian neuroethology since the early 1960’s. He is known for his idea that young birds initially remember a tutor song and use the memory as a template to guide the development of their own song. He was the fi rst to show that estrogen prevents programmed cell death in female zebra fi nches. He also pioneered work on the brain mechanisms of sound localization by barn owls. He has trained many students and postdoctoral fellows who became leading neuroethologists.
  • Crawford E-Transcript.Ptx

    Crawford E-Transcript.Ptx

    VIDEOTAPED DEPOSITION OF LESTER M. CRAWFORD, D.V.M., PH.D. CONDUCTED ON WEDNESDAY, MAY 24, 2006 Page 1 1 UNITED STATES DISTRICT COURT 2 EASTERN DISTRICT OF NEW YORK 3 - - - - - - - - - - - - - - X 4 ANNIE TUMMINO, et al., : 5 Plaintiffs, : 6 v. : No. 05-CV-366(ERK/VVP) 7 ANDREW C. VON ESCHENBACH, : (Korman, C.J.) 8 as Acting Commissioner of : (Pohorelsky, M.J. 9 The Food & Drug : 10 Administration, : 11 Defendant. : 12 - - - - - - - - - - - - - - X 13 14 Videotaped Deposition Of 15 LESTER M. CRAWFORD, D.V.M., Ph.D. 16 Washington, D.C. 17 Wednesday, May 24, 2006 18 9:11 a.m. 19 20 Job No. 1-78974 21 Pages 1 - 244 22 Reported by: Jacquelyn C. Jarboe L.A.D. REPORTING & DIGITAL VIDEOGRAPHY - (800) 292-4789 (202) 861-3410 (800) 292-4789 (301) 762-8282 (703) 288-0026 (410) 539-3664 VIDEOTAPED DEPOSITION OF LESTER M. CRAWFORD, D.V.M., PH.D. CONDUCTED ON WEDNESDAY, MAY 24, 2006 Page 2 1 Videotaped deposition of LESTER M. CRAWFORD, 2 D.V.M., Ph.D., held at the offices of: 3 4 5 Arnold & Porter LLP 6 555 Twelfth Street, Northwest 7 Washington, D.C. 20004 8 (202) 827-1152 9 10 11 12 13 14 Pursuant to agreement, before Jacquelyn C. 15 Jarboe, Notary Public in and for the District of 16 Columbia. 17 18 19 20 21 22 L.A.D. REPORTING & DIGITAL VIDEOGRAPHY - (800) 292-4789 (202) 861-3410 (800) 292-4789 (301) 762-8282 (703) 288-0026 (410) 539-3664 VIDEOTAPED DEPOSITION OF LESTER M. CRAWFORD, D.V.M., PH.D.
  • FDA Finally Approves Plan B—But with Restrictions

    FDA Finally Approves Plan B—But with Restrictions

    FDA finally approves Plan B—but with restrictions New York Janice Hopkins Tanne The US Food and Drug Administration has finally approved the emergency contraceptive Plan B for sale over the counter to women aged 18 or over. Plan B is a two pill, high dose regimen of the oral contraceptive levonorgestrel. It is about 90% effective in preventing pregnancy when taken within 72 hours of unprotected sex. Plan B will be available towards the end of the year at a cost of $25 (£13; €20) to $40. Women will have to request it from a pharmacist in a pharmacy that is licensed to sell it or from a health clinic. They will have to show government issued identification, such as a driver’s licence, proving they are aged 18 or older. Younger women will need a doctor’s prescription. Men aged 18 or older will also be able to buy the drug for their partner, a move that has raised concern that they may buy it for women under 18. It will not be sold at petrol stations or in convenience stores. The manufacturer, Barr Pharmaceuticals, will survey pharmacies to see that they follow the rules. The FDA’s acting commissioner, Andrew von Eschenbach, approved Plan B three days after President Bush said that he supported approval of the drug for women aged over 18, with prescription only access for younger women. In his approval letter Dr von Eschenbach noted that buyers of nicotine patches and some other drugs already had to prove they were at least 18. The approval came nearly three years after the FDA’s own expert advisory committees and professional staff recommended that the drug be available over the counter for women of all ages.
  • The Need to Shorten the Prescription Drug Approval Process

    The Need to Shorten the Prescription Drug Approval Process

    Valparaiso University Law Review Volume 27 Number 1 Fall 1992 pp.95-137 Fall 1992 Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process Mark A. Kassel Follow this and additional works at: https://scholar.valpo.edu/vulr Part of the Law Commons Recommended Citation Mark A. Kassel, Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process, 27 Val. U. L. Rev. 95 (1992). Available at: https://scholar.valpo.edu/vulr/vol27/iss1/3 This Notes is brought to you for free and open access by the Valparaiso University Law School at ValpoScholar. It has been accepted for inclusion in Valparaiso University Law Review by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. Kassel: Getting There First With the Best: The Need to Shorten the Presc Notes GETTING THERE FIRST WITH THE BEST: THE NEED TO SHORTEN THE PRESCRIPTION DRUG APPROVAL PROCESS I. INTRODUCTION Due to unnecessary time delays, high costs and safety concerns, drug regulation in the United States is in need of reform.' The United States consistently lags behind the rest of the developed world in the approval of new, innovative, and efficient medications.2 Therefore, the Food and Drug Administration (FDA) needs to implement creative and effective changes in the prescription drug approval process3 in order to protect the health of the American public. Most Americans think that the FDA's stringent process for approving new prescription drugs guarantees that prescription drugs are successfully monitored.4 The American public assumes that safe and innovative drugs are made available to the public as quickly' and cost effectively6 as possible, while unsafe7 products are kept off the market.' However, this confidence placed in the FDA is unwarranted.
  • 1 United States District Court Eastern District of New York

    1 United States District Court Eastern District of New York

    Case 1:05-cv-00366-ERK-VVP Document 285 Filed 03/30/09 Page 1 of 52 PageID #: <pageID> UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -----------------------------------------------------------------X ANNIE TUMMINO et al., Plaintiffs, MEMORANDUM & ORDER - against - No. 05-CV-366 (ERK)(VVP) FRANK M. TORTI,∗ Acting Commissioner of the Food and Drug Administration, Defendant. -----------------------------------------------------------------X KORMAN, J.: Plan B is an emergency contraceptive that can be used to reduce the risk of unwanted pregnancy after sexual intercourse. When used as directed, it can reduce the risk of pregnancy by up to 89 percent. Plan B acts mainly by stopping the release of an egg from an ovary. It may also prevent sperm from fertilizing an egg that has been released or, if fertilization has already occurred, block implantation of the resulting embryo in the uterus. Plan B does not have any known serious or long-term side effects, though it may have some mild and short-term side effects, such as nausea or abdominal pain, in some users. The approved dosage of Plan B is two pills taken 12 hours apart, each containing 0.75 mg of levonorgestrel, a synthetic hormone similar to the naturally occurring hormone progesterone. Because the drug works best when taken within 24 hours of sexual intercourse, it is commonly referred to as a “morning-after pill.” Nevertheless, the drug is effective if the first dose is taken within 72 hours of sexual intercourse. ∗ Pursuant to Federal Rule of Civil Procedure 25(d), Acting Commissioner Frank M. Torti has been substituted for former Commissioner Andrew C.
  • Vrwinter06weblinked.Pdf

    Vrwinter06weblinked.Pdf

    eterinary REPORT WINTER 2006 | VOL. 29 | NO. 1 2 Meet David Williams State-of-the-art 3 small animal surgery suites and ICU/ER College Unveils Facility Plan 25 Thank You, College Supporters Equine Sports Medicine Clinic Academic Commons, to support expanded veterinary class size Dean’s Column In this issue Spotlight on the Veterinary Teaching Features Hospital New Clinical Department By Herb Whiteley Head . 1 For many alumni and friends of the College, the Veterinary Teaching Facility Plan . 2 Hospital is the most visible and tangible aspect of our institution. The Ugandan Connection . 4 This is where your beloved companion animals and valuable agricul- tural assets—or those of your referred clients—receive expert care. Illinois Program Has Global This is where your future veterinarian or your future colleagues in Impact on Animal Health . 5 practice receive their capstone education. Without a Operation Polar Bear . 6 This is where the newest surgical approaches, best diagnostic tests, doubt, the and state-of-the-art treatment protocols are developed and tested. Joan Embery . 7 Without a doubt, the Veterinary Teaching Hospital participates in Veterinary News from the Zoos . 7 all aspects of our mission and vision, contributing indispensably to the Teaching College’s leadership in veterinary education, scholarship, and public engagement. Hospital College News . 8 This past summer, the teaching hospital became an independent participates College unit equivalent to the three academic departments and the Research News . .10 in all aspects Veterinary Diagnostic Laboratory. A new faculty-level position, director New Faces . .12 of the Veterinary Teaching Hospital, was created. of our mission This leader will work very closely with Dr.
  • Division of Extramural Activities Annual Report 2002

    Division of Extramural Activities Annual Report 2002

    Division of Extramural Activities Annual Report 2002 National Institutes of Health National Cancer Institute Molecular Diagnosis of Cancer Gene expression profiling using DNA microarrays is a technology that arose as a consequence of the Human Genome Project. With DNA microarrays, it is possible to determine the activity (“expression”) of tens of thousands of genes in parallel on microarray plates. The expression of genes influences the biological behavior of a cell because it dictates which proteins the cell can make and gives cells their unique characteristics. In the DNA microarray images shown at the bottom of the cover illustration, each spot represents a different human gene. Red, yellow, and green spots indicate that a gene is expressed at high, intermediate, and low levels, respectively. The pattern of expression of all of the genes in a cell constitutes its gene expression “profile.” Using DNA microarrays, different types of normal and malignant cells can be distinguished from one another because they have distinct gene expression profiles. Shown at the top of the cover illustration are photomicrographs of lymph node biopsies from two patients with diffuse large B cell lymphoma. The tumor at the right belongs to the germinal center B cell-like subgroup of diffuse large B cell lymphoma. Patients with this lymphoma type have a relatively favorable 5-year survival rate of 59% following multi-agent chemotherapy. The tumor at the left belongs to the activated B cell-like subgroup of diffuse large B cell lymphoma. Patients with this lymphoma type have a less favorable 5-year survival rate of 31%. Although the tumors from these patients were indistinguishable histologically, they had striking differences in their gene expression profiles, as exemplified by the microarray images shown below each lymphoma subgroup.
  • Donald Griffin Was Able to Affect a Major Revolution in What Scien- Tists Do and Think About the Cognition of Nonhuman Ani- Mals

    Donald Griffin Was Able to Affect a Major Revolution in What Scien- Tists Do and Think About the Cognition of Nonhuman Ani- Mals

    NATIONAL ACADEMY OF SCIENCES DONALD R. GRIFFIN 1915– 2003 A Biographical Memoir by CHARLES G. GROSS Any opinions expressed in this memoir are those of the author and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoirs, VOLUME 86 PUBLISHED 2005 BY THE NATIONAL ACADEMIES PRESS WASHINGTON, D.C. DONALD R. GRIFFIN August 3, 1915–November 7, 2003 BY CHARLES G. GROSS OST SCIENTISTS SEEK—but never attain—two goals. The M first is to discover something so new as to have been previously inconceivable. The second is to radically change the way the natural world is viewed. Don Griffin did both. He discovered (with Robert Galambos) a new and unique sensory world, echolocation, in which bats can perceive their surroundings by listening to echoes of ultrasonic sounds that they produce. In addition, he brought the study of animal consciousness back from the limbo of forbidden topics to make it a central subject in the contemporary study of brain and behavior. EARLY YEARS Donald R. (Redfield) Griffin was born in Southampton, New York, but spent his early childhood in an eighteenth- century farmhouse in a rural area near Scarsdale, New York. His father, Henry Farrand Griffin, was a serious amateur historian and novelist, who worked as a reporter and in advertising before retiring early to pursue his literary inter- ests. His mother, Mary Whitney Redfield, read to him so much that his father feared for his ability to learn to read. His favorite books were Ernest Thompson Seton’s animal 3 4 BIOGRAPHICAL MEMOIRS stories and the National Geographic Magazine’s Mammals of North America.
  • The National Academies Committee on a New Government-University

    The National Academies Committee on a New Government-University

    NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006. It was prepared by CASET Associates and is not an official report of The National Academies. Opinions and statements included in the transcript are solely those of the individual persons or participants at the workshop, and are not necessarily adopted or endorsed or verified as accurate by The National Academies. The National Academies Committee on a New Government-University Partnership for Science and Security September 28, 2006 Stanford University Bechtel Conference Center 616 Serra Mall, Encina Hall Stanford, CA Proceedings by: CASET Associates, Ltd. 10201 Lee Highway, suite 180 Fairfax, Virginia 22030 (703) 352-0091 NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006. It was prepared by CASET Associates and is not an official report of The National Academies. Opinions and statements included in the transcript are solely those of the individual persons or participants at the workshop, and are not necessarily adopted or endorsed or verified as accurate by The National Academies. TABLE OF CONTENTS Page Introductions and Purpose of Meeting Jacques S. Gansler and Alice P. Gast 1 Security Concerns at National and University Laboratories Siegfried S. Hecker 3 Discussion 26 International Collaborations Jonathan Dorfan 40 Discussion 56 National Security and Academic Publishing Donald Kennedy 64 Discussion 77 Open Discussion: Moving Forward 86 NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006.
  • Carefirst Doctors Earn $1.4 Million in P4P Rewards

    Carefirst Doctors Earn $1.4 Million in P4P Rewards

    46 Practice Trends I NTERNAL M EDICINE N EWS • November 15, 2006 P OLICY & PRACTICE tive care. During the first year, participat- CMS Curbs Improper Claims ing physicians will be paid for reporting Medicare is on track in 2006 to further re- Ex-FDA Chief Crawford Guilty Pilot P4P for Small Practices baseline information. In the 2 succeeding duce the number of fraudulent and inap- Former Food and Drug Administration The Centers for Medicare and Medicaid years, practices will submit quality data; propriate claims being submitted. CMS is Commissioner Lester M. Crawford, Services is seeking 800 solo and small- to they can earn up to $10,000 per physician reporting that 4% of claims were im- D.V.M., has pleaded guilty to lying about medium-sized group practices to partici- or up to $50,000 per practice for meeting proper in 2006, down from 5% the previ- stock he held during his tenure, in viola- pate in a 3-year pilot pay-for-performance benchmarks endorsed by the National ous year and from 14% in 1996, leading to tion of federal conflict-of-interest and project. The Medicare Care Management Quality Forum. The measures are similar $11 billion less in improper payments over stock ownership rules. Dr. Crawford was Performance Demonstration is limited to to those being used in Medicare’s Physician the last 2 years. To determine the error charged with two misdemeanors and is practices in Arkansas, California, Massa- Voluntary Reporting Program. At the end rate, CMS randomly sampled 160,000 scheduled to be sentenced Jan. 22 in Fed- chusetts, and Utah that are the main of the 3-year project, CMS and the Agency claims submitted from April 2005 to eral District Court in Washington.